



TOP 10 NET AMOUNT PAID-CY 2022(Chart 2)

Therapeutic Category	PRODUCT NAME	GENERIC NAME	LABELER NAME	Brand or Generic (B/G)	Rank by Net Amount Paid 1= Highest Net Spend	AVERAGE PERCENT INCREASE (Over One Year)	GROSS AMOUNT PAID*	Specialty (YES/NO)	Appeared on Previous Year List (YES/NO)	Appeared on this year's GROSS (WAC) COST LIST
Antipsoriatics	STELARA	Ustekinumab	JANSSEN BIOTECH, INC	B	1	27%	\$ 5,824,224	YES	YES	NO
Hormone related	LUPRON DEPOT-PED	Acetate (3 Month) Inj Pediatric	ABBVIE INC	B	2	19%	\$ 862,028	NO	NO	NO
Antiasthma - Monoclonal	XOLAIR	Omalizumab	GENENTECH, INC.	B	3	19%	\$ 560,541	YES	YES	NO
Insulin	HUMALOG KWIK INJ 200/ML	Insulin Lispro	ELI LILLY AND COMPANY	B	4	24%	\$ 564,722	NO	YES	NO
Anticonvulsants	VIMPAT	Lacosamide	UCB, INC.	B	5	23%	\$ 355,402	NO	NO	NO
Multiple Sclerosis Agents	COPAXONE INJ 40MG/ML	Glatiramer Acetate	TEVA NEUROSCIENCE, INC.	B	7	35%	\$ 292,892	YES	NO	NO
Anticonvulsants	TOPIRAMATE ER	Topiramate	UPSHER-SMITH LAB., LLC.	G	6	127%	\$ 74,082	NO	NO	NO
Inflammatory Bowel Agents	CIMZIA	Certolizumab Pegol	UCB, INC.	B	8	127%	\$ 187,774	YES	NO	NO
Contraceptives IUD	MIRENA	Levonorgestrel (IUD)	BAYER HEALTHCARE PHARM, INC	B	9	19%	\$ 59,103	YES	NO	NO
Hypnotics - Tricyclic Agents	DOXEPIN HYDROCHLORIDE	Doxepin HCl (Sleep)	CURRAX PHARM., LLC.	G	10	41%	\$ 8,970	NO	NO	NO

\*DVHA is prohibited from publishing drug-specific net cost information. The gross cost to DVHA for each drug listed is provided as a benchmark. This will not align in rank order with the net cost of the drug to the State.

This is an ndc specific list. Where multiple ndcs were included the gross amount paid was totaled and the average percent increase